Daily non-political popular news in brief.

Wesley Research Institute study targets pharmacists to help diabetes sufferers

07-05-2007 · EurekAlert!

A new Wesley Research Institute project aims to make it much easier for people to manager their type 2 diabetes by using community pharmacists.

Keywords: wesley, research, institute, study, targets, pharmacists, diabetes, sufferers, target, pharmacist, diabete, sufferer

« Previous | Next »

Similar news on "Wesley Research Institute study targets pharmacists to help diabetes sufferers":

Study identifies glucose 'sensor' that plays dual role in glucose metabolism and fat synthesis
12-26-2006 · EurekAlert!
In a new study, scientists at the Scripps Research Institute have described for the first time a glucose-activated sensor that acts as a switch to decrease production of endogenous glucose in the liver, and increase conversion of glucose to fat for storage in adipose tissue. This dual action makes the sensor, Liver X Receptor, a potential target for new therapies aimed at obesity and diabetes. The research may also have implications for heart disease and stroke.
Similar news · Read more »
Genetic 'roadblock' hoped to inspire future type 2 diabetes research
10-02-2007 · EurekAlert!
A team of Mount Sinai Hospital researchers has found that a 'genetic roadblock' identified in a recent study could pave the way toward novel treatments for type 2 diabetes. In the study, researchers from the Samuel Lunenfeld Research Institute of Mount Sinai Hospital found the first genetic evidence that the elimination of the gene for glycogen synthase kinase-3 in mice sensitizes the animals to insulin.
Similar news · Read more »
Promising target for new atherosclerosis therapies linked to leukemia
11-01-2006 · EurekAlert!
In recent years, scientists studying inflammation and atherosclerosis have seen their respective fields converging, with research findings showing chronic inflammation as a driver of the atherosclerotic process. Now, in a new study, scientists at the Wistar Institute pursuing a promising new immune-system target for anti-atherosclerosis therapies have discovered another convergence: An unwanted potential side effect of any such therapies is a dangerous blood cancer called chronic myelogenous leukemia, or CML.
Similar news · Read more »
Study reveals molecular basis of botulism toxin's deadly activity
12-14-2006 · EurekAlert!
Scientists at the Scripps Research Institute, the University of Wisconsin School of Medicine and Public Health, and the Howard Hughes Medical Institute have revealed in atomic detail how the toxins that cause botulism target and bind to nerve cells. This new understanding could ultimately lead to new ways for treating botulism, as well as to improved therapies for nervous system diseases such as dystonias, cerebral palsy and multiple sclerosis.
Similar news · Read more »
VBI research offers potential route to diabetes therapeutics
01-22-2007 · EurekAlert!
Work at Virginia Bioinformatics Institute is providing important information for researchers designing drugs for type 2 diabetics by helping researchers to identify potential targets for docking inhibitors that will slow down, but not fully eliminate, the body's overproduction of glucose.
Similar news · Read more »
Advance in understanding of blood pressure gene could lead to new treatments
02-04-2007 · EurekAlert!
Research by scientists at UCL (University College London) has clearly demonstrated for the first time the structure and function of a gene crucial to the regulation of blood pressure. The discovery could be important in the search for new treatments for illnesses such as heart disease, the UK's biggest killer. In a paper published online today in Nature Medicine, the team, led by Professor Patrick Vallance and Dr James Leiper, UCL Department of Medicine, reveal the role of the human gene dimethylarginine dimethylaminohydrolase (DDAH), showing that loss of DDAH activity disrupts nitric oxide (NO) production. NO is critical in the regulation of blood pressure, nervous system functions and the immune system. The role of DDAH is to break down modified amino acids (Asymmetric dimethylarginine (ADMA) and monomethyl arginine (L-NMMA)) that are produced by the body and have been shown to inhibit NO synthase. These molecules accumulate in various disease states including diabetes, renal failure and pulmonary and systemic hypertension, and their concentration in plasma (the fluid component of blood) is strongly predicative of cardiovascular disease and death. In a healthy human body, the majority of ADMA is eliminated through active metabolism by DDAH. Scientists have hypothesised that if DDAH function is impaired, NO production is reduced, and that this could be an important feature of increased cardiovascular risk. To examine this pathway in more detail, the researchers deleted the DDAH gene in mice. These mice went on to develop hypertension, or high blood pressure. They also designed specific inhibitors (small molecules) which bind to the active site of human DDAH. These small molecule inhibitors also induced hypertension in mice, confirming the importance of DDAH in the regulation of blood pressure. Dr Leiper, UCL Medicine, said: “These genetic and chemical approaches to disrupt DDAH showed remarkably consistent results, and provide compelling evidence that loss of DDAH function increases the concentration of ADMA and thereby disrupts vascular NO signalling. “There has been considerable scientific interest in this pathway and the role of ADMA as a novel risk factor, but so far there's been little evidence to support the idea that it's a cause of disease, rather than just a marker. Genes and their pathways are crucial to our understanding of cardiovascular disease and a better understanding of DDAH-1 could lead to important new treatments. “It could help us to establish if genetic variation predisposes certain people to these diseases, or whether environmental factors exert some of their effects through modulation of DDAH activity. “Our research also shows that this pathway could be harnessed therapeutically to limit production of NO in certain situations where too much nitric oxide is a bad thing; for example, hypotension and septic shock. These are some of the biggest problems in intensive care medicine and there is a huge unmet need for drug treatments.” The study, which was carried out at UCL's Rayne Institute, was funded by grants from the British Heart Foundation, the Wellcome Trust and the Medical Research Council. Professor Jeremy Pearson, Associate Medical Director of the British Heart Foundation, said: "The unexpected finding in the 1980s that a simple gas, nitric oxide (NO), is made by cells in the blood vessel wall and is a powerful control of blood vessel relaxation led to the award of the Nobel Prize in 1998 to its discoverers. "More recently, there has been increasing evidence that impairment of NO production is likely to be an important factor in the development of heart and circulatory disease, but the mechanisms responsible are not fully understood. "This study suggests for the first time that the loss of the activity of the enzyme DDAH-1 leads to reduced NO production and may cause heart and circulatory disease. These findings are likely to be important in the search for new ways to optimise the health of our blood vessels." ### Notes for Editors 1. For more information, please contact Ruth Metcalfe in the UCL Media Relations Office on tel: +44 (0)20 7679 9739, mobile: +44 (0)7990 675 947, out of hours: +44 (0)7917 271 364, e-mail: r.metcalfe@ucl.ac.uk2. 'Disruption of methylarginine metabolism impairs vascular homeostasis' is published in the February issue of the journal Nature Medicine. Advance online publication is embargoed to 18.00 GMT (13.00 US Eastern) Sunday 4 February 2007. Journalists can obtain copies of the paper by contacting the UCL Media Relations Office.3. The study was funded by the British Heart Foundation, the Wellcome Trust and the Medical Research Council. About UCL Founded in 1826, UCL was the first English university established after Oxford and Cambridge, the first to admit students regardless of race, class, religion or gender, and the first to provide systematic teaching of law, architecture and medicine. In the government's most recent Research Assessment Exercise, 59 UCL departments achieved top ratings of 5* and 5, indicating research quality of international excellence. UCL is the fourth-ranked UK university in the 2006 league table of the top 500 world universities produced by the Shanghai Jiao Tong University. UCL alumni include Mahatma Gandhi (Laws 1889, Indian political and spiritual leader); Jonathan Dimbleby (Philosophy 1969, writer and television presenter); Junichiro Koizumi (Economics 1969, Prime Minister of Japan); Lord Woolf (Laws 1954, Lord Chief Justice of England & Wales); Alexander Graham Bell (Phonetics 1860s, inventor of the telephone), and members of the band Coldplay.
Similar news · Read more »
Allergy molecule identified
07-01-2007 · EurekAlert!
A vital molecule for resistance to food allergy has been identified offering a potential target for therapy.There is currently no way to treat food allergy; sufferers must avoid certain foods and keep adrenaline at hand.Scientists led by Dr. Claudio Nicoletti at the Institute of Food Research in Norwich have found a molecule that is absent during allergic responses. He suggests that by delivering allergens with this molecule, allergic reactions could be controlled.
Similar news · Read more »
Genome-wide search unearths surprising clues for diabetes and triglycerides
04-26-2007 · EurekAlert!
Scientists from the Broad Institute of Harvard and MIT, Lund University and Novartis today announced the discovery of three unsuspected regions of human DNA that contain clear genetic risk factors for type 2 diabetes, and another that is associated with elevated blood triglycerides. The study is among the first to apply a suite of genomic resources to clinical research, including the Human Genome Project, the SNP and HapMap Projects, and genome-scale laboratory and analytical tools.
Similar news · Read more »
Deficient regulators in the immune system responsible for type 1 diabetes
01-24-2008 · EurekAlert!
The reduction in the regulating capacity of some regulators of the immune system (called CD4+Treg cells,) seems to play a critical role in the onset of type 1 diabetes, as demonstrated in the latest study by Dr. Ciriaco Piccirillo, a researcher in the department of microbiology and immunology at the Research Institute of the McGill University Health Center and the principal investigator for this project. This study was published this month in the journal Diabetes.
Similar news · Read more »
Scientists identify 2 distinct Parkinson's networks
07-09-2007 · EurekAlert!
Parkinson's that causes tremors, rigidity and slowed movements also targets another brain network that regulates cognitive thought and the ability to carry out everyday tasks. David Eidelberg, MD, head of the Center for Neurosciences at the Feinstein Institute for Medical Research, and his colleagues measured and quantified this network of brain regions during a five-year study of newly diagnosed Parkinson's patients who agreed to be followed several times over the course of the study.
Similar news · Read more »